Drug Monograph

Drug/Drug Class:	**Lazanda® (fentanyl citrate) nasal spray/ Transmucosal Immediate Release Fentanyl products**
Prepared for:	MO HealthNet
Prepared by:	Xerox Heritage, LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Lazanda® is now formulated to deliver a spray of 100 mcL of solution containing 300 mcg fentanyl base.
Manufacturer:	Depomed, Inc., Neward, CA 94560
Indications:	Lazanda® nasal spray is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
Costs:	$691.02 per bottle of Lazanda®. Wholesale Acquisition Cost
Summary of Findings:	The Division recommends adding this drug to the current TIRF clinical edit.
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ Clinical Edit
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Under Solicitation ☒ Appropriate Indications ☐ No PA Required

Prepared By: Luke Boehmer Pharm.D.
Date: August 29, 2016